Answers are grounded in this paper and cite their sources.
Adults with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have a poor prognosis. The median overall survival (OS) is 3–8 months with standard of care chemotherapy (SC) [1–3], with m...
No takes yet. Share an insight, caveat, or question.
Jabbour et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: